On April 28, 2026, the Supreme Court will hear oral arguments concerning skinny labeling, a contentious issue in the pharmaceutical industry.
This case could have significant implications for the availability of generic drugs, which are often more affordable alternatives to brand-name medications.
The focus will be on the practices surrounding skinny labels and how they influence the generic drug market.